Skip to content

Study · Measured the body's own peptide · 1987

3 results

Serum thymosin-alpha 1: lack of association between elevated levels and HIV infection.

Chen SJ, Ko HS

Clinical and experimental immunology1 Nov 1987Cited by 1 (Europe PMC)

PMID3427822 (opens in a new tab)PepBankPUB-03427822
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    Similar proportions of HIV-seropositive and seronegative subjects within each risk group had elevated serum thymosin alpha‑1 levels.

    In plain wordsThe body's own thymosin alpha‑1 levels were raised in similar shares of people with and without HIV antibodies.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeElevated serum thymosin-alpha 1 by HIV serostatus
    Study

    n = 143

    Comparator
    Seronegative subjects
    Outcome group
    Endogenous peptide levels · Infection

    Source sentences

    Summary
    We found that similar proportions of seropositive and seronegative subjects within each risk group showed elevated thymosin-alpha 1 levels.
    1 context sentence
    Summary · context
    We studied 143 individuals in two risk groups for AIDS (male homosexuals and haemophiliacs) for serum thymosin-alpha 1 and antibodies to HIV.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    Male homosexuals had significantly lower serum thymosin alpha‑1 levels than haemophiliacs.

    In plain wordsIn this study, male homosexuals had lower natural thymosin alpha‑1 levels than people with haemophilia; the reason is not known.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum thymosin-alpha 1 in male homosexuals versus haemophiliacs
    Study

    n = 143

    Comparator
    Haemophiliacs
    Outcome group
    Endogenous peptide levels · Infection

    Source sentences

    Summary
    In addition, the male homosexuals we studied showed significantly lower thymosin-alpha 1 levels than haemophiliacs but this difference remains to be explained.
    1 context sentence
    Summary · context
    We studied 143 individuals in two risk groups for AIDS (male homosexuals and haemophiliacs) for serum thymosin-alpha 1 and antibodies to HIV.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    Retesting after 6 months showed no significant increase in serum thymosin alpha‑1 in seropositive subjects or in those who developed HIV antibodies.

    In plain wordsAfter 6 months, the body's own thymosin alpha‑1 levels had not risen in people with HIV antibodies.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSerum thymosin-alpha 1 after 6 months retesting
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Infection

    Source sentences

    Summary
    Retesting after 6 months did not reveal significant increments over previous levels in seropositive subjects or in those developing HIV antibodies in the repeat samples.
    1 context sentence
    Summary · context
    We studied 143 individuals in two risk groups for AIDS (male homosexuals and haemophiliacs) for serum thymosin-alpha 1 and antibodies to HIV.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.